» Articles » PMID: 20192990

Antibodies to Citrullinated Proteins: Molecular Interactions and Arthritogenicity

Overview
Journal Immunol Rev
Date 2010 Mar 3
PMID 20192990
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

The discovery of antibodies specific for citrullinated protein epitopes [anti-citrullinated protein antibodies (ACPAs)] is a hallmark for the diagnosis and prognosis of rheumatoid arthritis (RA) and will also be a useful tool for understanding the fundamental pathologic processes. There are several essential questions pertaining to ACPA that remain to be explored, such as understanding the early specificity of the underlying T-cell recognition, whether the production of ACPA is a primary or secondary process, and in the event of such antibodies being arthritogenic, whether they could possibly regulate the disease development. To answer these questions, animal models are needed, but unfortunately ACPA is not a prominent feature of any of the classical animal models of RA. However, we showed recently that ACPA can be isolated from animals susceptible to collagen-induced arthritis that are specific for citrullinated type II collagen (CII). The citrulline specificity could be visualized, and the specificity is determined primarily by a direct interaction with citrulline. We also demonstrated that these antibodies are specific for the citrullinated epitopes and are pathogenic in vivo. A new hypothesis to explain how inflammation in RA can be directed to cartilaginous joints and be self-perpetuating is suggested, which involves recognition of post-translational modifications (glycosylation and citrullination) on CII by T and B cells that can have both arthritogenic and regulatory consequences.

Citing Articles

A subset of antibodies targeting citrullinated proteins confers protection from rheumatoid arthritis.

He Y, Ge C, Moreno-Giro A, Xu B, Beusch C, Sandor K Nat Commun. 2023; 14(1):691.

PMID: 36754962 PMC: 9908943. DOI: 10.1038/s41467-023-36257-x.


Inflammation-related citrullination of matrisome proteins in human cancer.

Rappu P, Suwal U, Siljamaki E, Heino J Front Oncol. 2022; 12:1035188.

PMID: 36531007 PMC: 9753687. DOI: 10.3389/fonc.2022.1035188.


A Novel Selective Inhibitor JBI-589 Targets PAD4-Mediated Neutrophil Migration to Suppress Tumor Progression.

Deng H, Lin C, Garcia-Gerique L, Fu S, Cruz Z, Bonner E Cancer Res. 2022; 82(19):3561-3572.

PMID: 36069973 PMC: 9532374. DOI: 10.1158/0008-5472.CAN-21-4045.


Key interactions in the trimolecular complex consisting of the rheumatoid arthritis-associated DRB1*04:01 molecule, the major glycosylated collagen II peptide and the T-cell receptor.

Ge C, Weisse S, Xu B, Dobritzsch D, Viljanen J, Kihlberg J Ann Rheum Dis. 2022; 81(4):480-489.

PMID: 35027402 PMC: 8921575. DOI: 10.1136/annrheumdis-2021-220500.


Pathogenic Role of Circulating Citrullinated Antigens and Anti-Cyclic Monoclonal Citrullinated Peptide Antibodies in Rheumatoid Arthritis.

Won P, Kim Y, Jung H, Rim Y, Sohn D, Robinson W Front Immunol. 2021; 12:692242.

PMID: 34305925 PMC: 8294326. DOI: 10.3389/fimmu.2021.692242.